TScan plans to cut 75% of their workforce and pivot to solid tumor cell therapy

TScan Therapeutics (Nasdaq: TCRX) announced a strategic reorganization that includes a workforce reduction of approximately 75%, shifting the company’s focus to an in vivo-engineered T cell receptor (TCR-T) program targeting solid tumors.

The Waltham, Mass.-based company is advancing two product candidates — one targeting PRAME and one targeting MAGE-A4 — into IND-enabling studies. TScan plans to share preclinical data in Q1 2027, file its first investigational new drug (IND) application in Q3 2027, and initiate Phase 1 development in Q4 2027.

The reorganization is expected to generate cumulative cost savings of $55 million through the end of 2027. The company said its available cash, cash equivalents, and marketable securities as of June 30, 2026, are expected to fund operations into Q4 2027.

TScan also announced it is pausing further enrollment in its Phase 3 ALLOHA-2 study of TSC-101, a therapy for hematologic malignancies, citing insufficient capital to complete the trial. Seven patients already enrolled on the treatment arm will continue to be monitored. The company said it is actively seeking strategic partners to advance the heme malignancies program.